Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1173-1185

  Liu, Zhigang ^a,i   Zhao, Xiumei ^b,c,j   Mao, Hua ^b,c   Baxter, Patricia A ^b,c   Huang, Yulun ^b,c   Yu, Litian ^b,c   Wadhwa, Lalita ^d   Su, Jack M ^c   Adesina, Adekunle ^c,e   Perlaky, Lazlo ^c   Hurwitz, Mary ^c,d,e,f,g   Idamakanti, Neeraja ^h   Police, Seshidhar Reddy ^h   Hallenbeck, Paul L ^h   Hurwitz, Richard L ^c,d,e,f,g   Lau, Ching C ^c   Chintagumpala, Murali ^c   Blaney, Susan M ^c   Li, Xiao Nan ^b,c  

^a Diana Helis Henry Medical Research Foundation   (United States)

^b Laboratory of Molecular Neuro oncology   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d Center for Cell and Gene Therapy   (United States)

^e Department of Pathology ^*  (United States)

^f Molecular and Cellular Biology   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Neotropix Inc   (United States)

ⁱ SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^j THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

more..

Author keywords

malignant glioma; oncolytic virus; orthotopic xenograft; sialic acid; SVV 001

Indexed keywords

LECTIN; ONCOLYTIC VIRUS; ONCOLYTIC VIRUS SVV 001; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL RENEWAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PICORNAVIRUS; PROTEIN BINDING; TUMOR CELL; TUMOR CELL CULTURE; TUMOR VOLUME; TUMOR XENOGRAFT; VIROGENESIS; VIRUS PARTICLE;

MALIGNANT GLIOMA; ONCOLYTIC VIRUS; ORTHOTOPIC XENOGRAFT; SIALIC ACID; SVV-001;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; INJECTIONS, INTRAVENOUS; MICE; MICE, SCID; N-ACETYLNEURAMINIC ACID; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PICORNAVIRIDAE; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883168783     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not065     Document Type: Article

References (52)

1. Glas M, Happold C, Rieger J, et al. Long-term survivalofpatients with glio-blastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27:1257-1261.
2. Shih CS, Hale GA, Gronewold L, et al. High-dose chemotherapy with au-tologous stem cell rescue for children with recurrent malignant brain tumors. Cancer. 2008;112:1345-1353. (Pubitemid 351429750)
3. Diehn M, Cho RW, Clarke MF. Therapeuticimplicationsofthecancerstem cell hypothesis. Semin Radiat Oncol. 2009;19:78-86.
4. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760. (Pubitemid 44949604)
5. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100: 15178-15183. (Pubitemid 37518036)
6. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17: 362-375.
7. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-349.
8. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther. 2009;17:1677-1682.
9. Everson RG, Gromeier M, Sampson JH. Virusesinthe treatmentof malignant glioma. Expert Rev Neurother. 2007;7:321-324.
10. Studebaker AW, Hutzen B, Pierson CR, et al. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated me-dulloblastoma. Neuro Oncol. 2012;14:459-470.
11. Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus. 2006;20:E19.
12. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J.Oncolytic ad-enovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009;9:422-427.
13. Wilcox ME, Yang W, Senger D, et al. Reovirusasanoncolyticagentagainst experimental human malignant gliomas. J Natl Cancer Inst. 2001;93: 903-912. (Pubitemid 32624647)
14. Lun X, Senger DL, Alain T, et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst. 2006;98:1546-1557. (Pubitemid 44680906)
15. Geletneky K, Kiprianova I, Ayache A, et al. Regressionofadvancedrat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol. 2010;12:804-814.
16. Lun X, Alain T, Zemp FJ, et al. Myxoma virus virotherapy for glioma in im-munocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010;70:598-608.
17. Zulkifli MM, Ibrahim R, Ali AM, et al. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurol Res. 2009;31:3-10.
18. Dobrikova EY, Broadt T, Poiley-Nelson J, et al. Recombinantoncolyticpoliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther. 2008;16:1865-1872
19. Heikkila JE, Vaha-Koskela MJ, Ruotsalainen JJ, et al. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One. 2010;5:e8603
20. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of delta-24-RGD in brain tumor stem cells: role of autophagiccel death. J Natl Cancer Inst. 2007;99:1410-1414 (Pubitemid 351767180)
21. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69: 3472-3481
22. Friedman GK, Langford CP, Coleman JM, et al. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol. 2009;95:199-209.
23. Skog J, Edlund K, Bergenheim AT, Wadell G. Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Mol Ther. 2007;15:2140-2145. (Pubitemid 350148930)
24. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2008;16:262-278.
25. Myers R, Harvey M, Kaufmann TJ, et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carci-noembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther. 2008;19: 690-698. (Pubitemid 352009918)
26. Lun XQ, Jang JH, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res. 2009;15:2777-2788.
27. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus delta24-RGD to human gliomas. Cancer Res. 2009; 69:8932-8940.
28. Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley virus, asystemi-cally deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99:1623-1633
29. Venkataraman S, Reddy SP, Loo J, et al. Crystallization and preliminary x-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008;64:293-296. (Pubitemid 351507826)
30. Wadhwa L, Hurwitz MY, Chevez-Barrios P, Hurwitz RL. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res. 2007;67:10653-10656. (Pubitemid 350145889)
31. Morton CL, Houghton PJ, Kolb EA, et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:295-303
32. Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17:888-895.
33. Yu L, Baxter PA, Zhao X, et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2010;13 14-27.
34. Campbell SA, Gromeier M. Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction. Onkologie. 2005;28:144-149. (Pubitemid 40522781)
35. Nilsson EC, Jamshidi F, Johansson SM, Oberste MS, Arnberg N. Sialic acid is a cellular receptor for Coxsackievirus A24 variant, an emerging virus with pandemic potential. J Virol. 2008;82:3061-3068. (Pubitemid 351329194)
36. Stevenson RA, Huang JA, Studdert MJ, Hartley CA. Sialic acid acts as a receptor for equine rhinitis A virus binding and infection. J Gen Virol. 2004;85:2535-2543. (Pubitemid 39214349)
37. Alexander DA, Dimock K. Sialic acid functions in enterovirus 70 binding and infection. J Virol. 2002;76:11265-11272. (Pubitemid 35231281)
38. Houghton PJ, Adamson PC, Blaney S, et al. Testingofnew agentsinchild-hood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8:3646-3657. (Pubitemid 35424754)
39. Shu Q, Wong KK, Su JM, et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008;26: 1414-1424.
40. Li XN, Shu Q, Su JM, et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetyla-tion and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005;4:1912-1922. (Pubitemid 43056974)
41. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glio-blastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391-403. (Pubitemid 43668737)
42. Shu Q, Antalffy B, Su JM, et al. Valproic acid prolongs survival timeof severe combinedimmunodeficient mice bearing intracerebellar orthotopic medul-loblastoma xenografts. Clin Cancer Res. 2006;12:4687-4694. (Pubitemid 44297822)
43. Hales LM, Knowles NJ, Reddy PS, et al. Complete genome sequenceanal-ysis of Seneca Valley virus-001, a novel oncolytic picornavirus. J Gen Virol. 2008;89:1265-1275.
44. Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A. Neurosphereassays: growth factors and hormone differencesin tumor and nontumor studies. Stem Cells. 2006;24:2851-2857. (Pubitemid 46053021)
45. Zhou L, Luo Y, Wu Y, Tsao J, Luo M. Sialylation of the host receptor may modulate entry of demyelinating persistent Theiler's virus. J Virol. 2000;74:1477-1485. (Pubitemid 30044098)
46. Bieler A, Mantwill K, Holzmuller R, et al. Impactof radiation therapyon the oncolytic adenovirus dl520: implications on the treatment of glioblasto-ma. Radiother Oncol. 2008;86:419-427. (Pubitemid 351343876)
47. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004;78:12665-12667. (Pubitemid 39458784)
48. Couceiro JN, Paulson JC, Baum LG. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium: the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 1993;29:155-165. (Pubitemid 23235070)
49. Nokhbeh MR, Hazra S, Alexander DA, et al. Enterovirus70bindstodiffer-ent glycoconjugates containing alpha2, 3-linked sialic acid on different cell lines. J Virol. 2005;79:7087-7094. (Pubitemid 40677340)
50. Kumlin U, Olofsson S, Dimock K, Arnberg N. Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respi Viruses. 2008;2: 147-154.
51. Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A. 2006;103:7753-7758.
52. Redaelli M, Franceschi V, Capocefalo A, et al. Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic propertiesin immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro Oncol. 2012;14:288-301.